Apoptosis during placentation

( views:, downloads: )
Journal Title:
Volume 53, Issue 06, 2001
Key Word:


  • [1]Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer, 1972, 26:239~257.
  • [2]Vaux DL, Korsmeyer SJ. Cell death in development. Cell, 1999, 96:245~254.
  • [3]Nelson DM. Apoptotic changes occur in syncytiotrophoblast of human placental villi where fibrin type fibrinoid is deposited at discontinuities in the villous trophoblast. Placenta, 1996, 17:387~391.
  • [4]Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol, 1997b, 177:1395~1401.
  • [5]Smith SC, Baker PN, Symonds EM. Placental apoptosis in normal human pregnancy. Am J Obstet Gynecol, 1997a, 177:57~65.
  • [6]Nagata S, Goldstein P. The Fas death factor. Science, 1995, 267:1449~1456.
  • [7]Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene, 1998, 17:3261~3270.
  • [8]Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature, 1997, 388:190~195.
  • [9]Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem, 1998, 273:33103~33106.
  • [10]Hetts SW. To die or not to die. An overview of apoptosis and its role in disease. JAMA, 1998, 279:300~307.
  • [11]Hockenbery D, Nufiez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 1990, 348:334~336.
  • [12]Hockenbery DM, Zutter M, Hickey W et al. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA, 1991, 88:6961~6965.
  • [14]Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell, 1993, 74:609~619.
  • [15]Basanez C, Nechushtan A, Drozhinin O et al. Bax, but not Bcl-xL, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci USA, 1999, 96(10):5492~5497.
  • [16]Marzioni D, Muhlhlhauser J, Crescimanno C et al. Bcl-2 expression in the human placenta and its correlation with fibrin deposits. Human Reprod, 1998, 13:1717~1722.
  • [17]Huppertz B, Frank H-G, Kingdom JC et al. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem Cell Biol, 1998, 110(5):495~508.
  • [18]Qiao S, Nagasaka T, Harada T et al. p53, Bax and Bcl-2 expression, and apoptosis in gestational trophoblast of complete hydatidiform mole. Placenta, 1998, 19(5~6):361~369.
  • [19]Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 1995, 270:1189~1192.
  • [20]Bellgrau D, Gold D, Selawry H et al. A role for CD95 ligand in preventing graft rejection. Nature, 1995, 377:630~632.
  • [21]Kaplan HJ, Leibole MA, Tezel T et al. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nature Med, 1999, 5:292~297.
  • [22]Bamberger AM, Schulte HM, Thuneke I et al. Expression of the apoptosis-inducing Fas ligand (FasL) in haman first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab, 1997, 82:3173~3175.
  • [23]Zorzi W, Thellin O, Coumans B et al. Demonstration of the expression of CD95 ligand transcript and protein in human placenta. Placenta, 1998, 19:269~277.
  • [24]Hunt Js, Vassmer D, Ferguson TA et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol, 1997, 158:4122~4128.
  • [25]Mor G, Gutierrez LS, Eliza M et al. Fas-Fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol, 1998, 402:89~94.
  • [26]Payne SG, Smith SC, Davidge ST et al. Death receptor Fas/Apo-1/CD95 expressed by human placental cytotrophoblasts does not mediate apoptosis. Biol Reprod, 1999, 60:1144~1150.
  • [27]Kaufmann SH, Desnoyers S,Ottaviano Y et al. Specific pro~teolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res, 1993, 53:3976~3985.
  • [28]McPherson JP, Goldenberg GJ. Induction of apoptosis by de~re~gu~lated expression of DNA topoisomerase II alpha. Cancer Res, 1998, 58:45l9~4524.
  • [29]Kothakota S, Azuma T, Reinhard C et al. Caspase 3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science, 1997, 278:294~298.
  • [30]Wen LP, Fahrni JA, Troie S et al. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem, 1997, 10:26056~26061.
  • [31]Hu ZY, Feng Q, Gao HJ et al. Studies on localization and possible role of plasminogen activator and inhibitors in early stage of placentation. Chin Sci Bull, 2000, 45(22):2056~2061.
  • [32]Liu YX, Hu ZY, Feng Q et al. Studies on expression and function of MT1-MMP and TIMP, in human early placentation. Chin Sci Bull, 2000, 45(6):607~611.
  • [33]Hu ZY, Liu YX, Zou RJ et al. Expression of tissue type and urokinase type plasminogen activators as well as their inhibitors type 1 and type 2 in the placenta of human and rhesus monkey. J Anatomy (London), 1999, 194:183~195.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn